Tourmaline Bio, Inc. (TRML)

Tourmaline Bio Market Cap

Tourmaline Bio has a market cap or net worth of $402.91 million as of May 2, 2024. Its market cap has increased by 263.31% in one year.

• Market Cap: 402.91M
• Enterprise Value: 200.14M
• 1-Year Change: 263.31%
• Ranking: #3108
• Category: Small-Cap
• Stock Price: $15.71

Market Cap Chart

Since May 7, 2021, Tourmaline Bio's market cap has decreased from $670.10M to $402.91M, a decrease of -39.87%. That is a compound annual growth rate of -15.68%.

Market Cap History

Date	Market Cap	% Change
Apr 30, 2024	406.00M	2.14%
Apr 29, 2024	397.50M	-1.14%
Apr 26, 2024	402.10M	-2.00%
Apr 25, 2024	410.30M	3.82%
Apr 24, 2024	395.20M	2.12%
Apr 23, 2024	387.00M	-2.64%
Apr 22, 2024	397.50M	0.33%
Apr 19, 2024	396.20M	-1.34%
Apr 18, 2024	401.60M	-6.12%
Apr 17, 2024	427.80M	-6.59%
Apr 16, 2024	458.00M	-5.95%
Apr 15, 2024	487.00M	-5.77%
Apr 12, 2024	516.80M	0.25%
Apr 11, 2024	515.50M	0.96%
Apr 10, 2024	510.60M	-13.02%
Apr 9, 2024	587.00M	-0.88%
Apr 8, 2024	592.20M	2.12%
Apr 5, 2024	579.90M	2.97%
Apr 4, 2024	563.20M	0.27%
Apr 3, 2024	561.70M	0.47%
Apr 2, 2024	559.10M	-7.39%
Apr 1, 2024	603.70M	2.79%
Mar 28, 2024	587.30M	-
Mar 27, 2024	587.30M	-3.86%
Mar 26, 2024	610.90M	0.05%

View and export this data all the way back to 2021. Sign Up Today.

Related Stocks

Company	Market Cap
Biomea Fusion	409.59M
Mersana Therapeutics	406.36M
Lexicon Pharmaceuticals	406.29M
Lexeo Therapeutics	405.26M
LENZ Therapeutics	403.68M
NeuroPace	401.22M
Replimune Group	397.79M
Revance Therapeutics	395.50M